Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: a double blind video-based analysis
- PMID: 19006186
- DOI: 10.1002/mds.22208
Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: a double blind video-based analysis
Abstract
The objective of this study is to assess dyskinesias in 34 Parkinson's disease patients randomized to receive bilateral fetal nigral transplantation with 4 donors per side (12), 1 donor per side (11), or placebo (11). Videotape recordings were performed at the baseline, 3, 6, 12, 18, and 24 month visits during the "practically defined off" (12 hours after last evening dopaminergic therapy) and "best on" (best response following morning dopaminergic therapy) states. Videotapes were analyzed in random order by a blinded investigator. Dyskinesias during "best on" (on-medication dyskinesia) were observed in all, but 1 patient at baseline, and in all patients at each subsequent visit. There were no differences between groups. No patient had dyskinesia at baseline in "practically-defined off" ("off-medication" dyskinesia). Following transplantation, off-medication dyskinesia was observed in 13 of 23 patients, but not in any patient in the placebo group (P = 0.019). There was no difference in dyskinesia score between patients in the 1 and 4 donor groups. On-medication dyskinesias were typically generalized and choreiform, whereas off-medication dyskinesias were usually repetitive, stereotypic movements in the lower extremities with residual Parkinsonism in other body regions. Off-medication dyskinesias are common following transplantation and may represent a prolonged form of diphasic dyskinesias.
(c) 2008 Movement Disorder Society.
Similar articles
-
Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial.Mov Disord. 2007 Jan 15;22(2):179-86. doi: 10.1002/mds.21226. Mov Disord. 2007. PMID: 17094088 Clinical Trial.
-
Deep brain stimulation in Parkinson's disease following fetal nigral transplantation.Mov Disord. 2008 Jul 15;23(9):1293-6. doi: 10.1002/mds.21768. Mov Disord. 2008. PMID: 18536037
-
Bilateral subthalamotomy in Parkinson's disease: initial and long-term response.Brain. 2005 Mar;128(Pt 3):570-83. doi: 10.1093/brain/awh397. Epub 2005 Feb 2. Brain. 2005. PMID: 15689366
-
[Dyskinesia caused by L-DOPA].Rev Neurol (Paris). 2002 Dec;158 Spec no 1:S92-101. Rev Neurol (Paris). 2002. PMID: 12690668 Review. French.
-
Rating scales for dyskinesias in Parkinson's disease.Mov Disord. 1999;14 Suppl 1:48-53. Mov Disord. 1999. PMID: 10493403 Review. No abstract available.
Cited by
-
A video-atlas of levodopa-induced dyskinesia in Parkinson's disease: terminology matters.Neurol Sci. 2024 Apr;45(4):1389-1397. doi: 10.1007/s10072-023-07209-6. Epub 2023 Nov 21. Neurol Sci. 2024. PMID: 37987930 Review.
-
Multiple system atrophy: current and future approaches to management.Ther Adv Neurol Disord. 2010 Jul;3(4):249-63. doi: 10.1177/1756285610375328. Ther Adv Neurol Disord. 2010. PMID: 21179616 Free PMC article.
-
α-Synuclein and neuronal cell death.Mol Neurobiol. 2013 Apr;47(2):466-83. doi: 10.1007/s12035-012-8327-0. Epub 2012 Aug 31. Mol Neurobiol. 2013. PMID: 22936307 Free PMC article. Review.
-
Levodopa-induced dyskinesia: a historical review of Parkinson's disease, dopamine, and modern advancements in research and treatment.J Neurol. 2022 Jun;269(6):2892-2909. doi: 10.1007/s00415-022-10963-w. Epub 2022 Jan 17. J Neurol. 2022. PMID: 35039902 Free PMC article. Review.
-
Cell based therapies in Parkinson's Disease.Ann Neurosci. 2011 Apr;18(2):76-83. doi: 10.5214/ans.0972.7531.1118209. Ann Neurosci. 2011. PMID: 25205926 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical